Dahong Yu

Rosiglitazone-Associated Fractures in Type 2 Diabetes

Steven E. Kahn, Bernard Zinman, John M. Lachin et al. · Diabetes Care · 2008 · 537 citations · Full text

Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 Diabetes

Steven E. Kahn, Bernard Zinman, Steven M. Haffner et al. · Diabetes · 2006 · 189 citations · Full text

Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial

Khaled Ezzedine, Elena Peeva, Yuji Yamaguchi et al. · Journal of the American Academy of Dermatology · 2022 · 126 citations · Full text

Translational Medicine, Active Nonsegmental Vitiligo, Pharmacology +5

Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain

Steven E. Kahn, Steven M. Haffner, Giancarlo Viberti et al. · Diabetes Care · 2009 · 40 citations · Full text

Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy

Dahong Yu, Susan J. Murdoch, Shamik Parikh et al. · Diabetes and Vascular Disease Research · 2006 · 22 citations · Full text